Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether dasatinib can be discontinued without
occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in
complete molecular remission(CMR) while on dasatinib.